BRL Medicine Inc. Receives IND Approval for CD19-Targeted CAR-T Therapy BRL-301 from CDE
Shanghai-based BRL Medicine Inc. has announced that it has received Investigational New Drug (IND) approval...
Bristol-Myers Squibb Q2 2023 Results Miss Estimates, Full-Year Guidance Revised Downward
US pharmaceutical company Bristol-Myers Squibb (BMS; NYSE: BMY) has released its financial report for the...
Pfizer Announces Leadership Shake-Up with Focus on Oncology R&D
Pfizer Inc., (NYSE: PFE) has announced significant changes in its Research and Development (R&D) leadership....
Roche Group’s H1 2023 Financial Report: Pharmaceuticals Grow While Diagnostics Dip
Swiss pharmaceutical giant Roche Group (SWX: ROG) has released its half-yearly financial report for 2023,...
MSD’s V116 Vaccine Shows Superior Immune Response in Phase III Trials
Merck, Sharp & Dohme (MSD; NYSE: MRK) has revealed positive topline results from two Phase...
Pharmaniaga Berhad and CSPC Pharmaceutical Group Broaden Collaboration in Pharma and Biopharma
Malaysia-based pharmaceutical company Pharmaniaga Berhad has announced the signing of a comprehensive collaboration with China’s...
Thermo Fisher Scientific Reports Q2 2023 Revenue Dip, Adjusts Full-Year Forecast
US-based life sciences giant Thermo Fisher Scientific Inc. (NYSE: TMO) has released its financial results...
AbbVie and Calibr Announce Strategic Collaboration to Advance Preclinical Research
AbbVie (NYSE: ABBV) and US-based Calibr, the nonprofit drug discovery division of San Diego research...
GSK Reports 4% YOY Sales Growth in Q2 2023, Upgrades Full-Year Guidance
UK-based pharmaceutical giant GlaxoSmithKline plc (GSK, NYSE: GSK) has released its financial report for the...
Everest Medicines Launches Xerava Antibiotic in China, Marking Commercial Milestone
Everest Medicines (HKG: 1952) has announced the commercial launch of its Xerava (eravacycline) antibiotic in...
Jiangsu Recbio’s Shingles Vaccine REC610 Accepted for Review by China’s NMPA
Jiangsu Recbio Technology Co., Ltd, a China-based company, has announced that the National Medical Products...
Mirxes Holding Company Secures USD 50 Million in Series D Financing for RNA Technology
Mirxes Holding Company Ltd, a Singapore-headquartered RNA technology company specializing in blood-based miRNA test kit...
Shanghai Henlius Completes Phase I/II Study for Anti-VEGF mAb HLX04-O in Wet AMD
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) subsidiary, Shanghai Henlius Biotech, Inc....
Innovent Biologics’ Altruist Biologics Partners with Longbio Pharma in RMB 500 Million Deal
Altruist Biologics, the Contract Development and Manufacturing Organization (CDMO) unit of China-based Innovent Biologics, Inc. (HKG:...
SSY Group Ltd Receives NMPA Approval for Stiripentol Dry Suspension for Dravet Syndrome
China-based SSY Group Ltd (HKG: 2005) has announced that it has received marketing approval from...
Novo Nordisk’s Turoctocog Alfa Pegol for Hemophilia A Accepted for Review by China’s CDE
The Center for Drug Evaluation (CDE) in China has indicated on its website that the...
Sisram Medical’s Alma Veil Launches in the US for Vascular Lesion Treatment
Alma Lasers, a subsidiary of Sisram Medical (HKG: 1696), has announced the commercial availability of...
AstraZeneca’s Eplontersen Gains Tacit Approval from CDE for ATTR-CM Clinical Study
The Center for Drug Evaluation (CDE) website indicates that UK pharmaceutical major AstraZeneca’s (AZ, NASDAQ:...
Kanova Biopharma Secures Over RMB 100 Million in Financing for Autoimmune and Oncology Pipeline
Kanova Biopharma, a Suzhou-based developer of antibodies focused on autoimmune diseases and oncology, has reportedly...
Boehringer Ingelheim Gets NMPA Approval for Phase II Study of BI 764532 in SCLC
Boehringer Ingelheim (BI) has announced that it has received approval from the National Medical Products...